- Home
- OGE vs JAZZ Comparison
OGE vs JAZZ Comparison
Compare OGE & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGE
- JAZZ
- Stock Information
- Founded
- OGE 1902
- JAZZ 2003
- Country
- OGE United States
- JAZZ Ireland
- Employees
- OGE N/A
- JAZZ N/A
- Industry
- OGE Electric Utilities: Central
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- OGE Utilities
- JAZZ Health Care
- Exchange
- OGE Nasdaq
- JAZZ Nasdaq
- Market Cap
- OGE 8.3B
- JAZZ 7.3B
- IPO Year
- OGE N/A
- JAZZ 2007
- Fundamental
- Price
- OGE $43.35
- JAZZ $121.43
- Analyst Decision
- OGE Buy
- JAZZ Buy
- Analyst Count
- OGE 4
- JAZZ 14
- Target Price
- OGE $45.00
- JAZZ $173.93
- AVG Volume (30 Days)
- OGE 913.5K
- JAZZ 567.6K
- Earning Date
- OGE 02-19-2025
- JAZZ 02-26-2025
- Dividend Yield
- OGE 3.87%
- JAZZ N/A
- EPS Growth
- OGE N/A
- JAZZ 458.10
- EPS
- OGE 1.93
- JAZZ 7.04
- Revenue
- OGE $2,791,500,000.00
- JAZZ $3,992,712,000.00
- Revenue This Year
- OGE $6.72
- JAZZ $7.51
- Revenue Next Year
- OGE $5.36
- JAZZ $6.84
- P/E Ratio
- OGE $22.05
- JAZZ $17.18
- Revenue Growth
- OGE N/A
- JAZZ 5.23
- 52 Week Low
- OGE $32.06
- JAZZ $99.06
- 52 Week High
- OGE $44.41
- JAZZ $134.17
- Technical
- Relative Strength Index (RSI)
- OGE 64.97
- JAZZ 47.48
- Support Level
- OGE $39.41
- JAZZ $118.72
- Resistance Level
- OGE $40.89
- JAZZ $124.66
- Average True Range (ATR)
- OGE 0.71
- JAZZ 2.79
- MACD
- OGE 0.30
- JAZZ -0.24
- Stochastic Oscillator
- OGE 93.59
- JAZZ 39.45
About OGE OGE Energy Corp
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution to 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.